(HealthDay News) — An electronic alert triggered on order of intravenous (IV) proton pump inhibitors (PPI) can decrease the proportion of IV PPIs ordered, according to a research letter published ...

Please provide your email address to receive an email when new articles are posted on . Incidence of 30-day rebleeding was 7.1% in the vonoprazan group and 10.4% in the proton pump inhibitor group.

Proton pump inhibitors (PPIs) are the most effective agents for treating acid related gastrointestinal (GI) disorders. The utilization of intravenous (IV) formulations of PPIs has dramatically ...

Objective and design: The use of proton pump inhibitors in acid-related diseases such as peptic ulcer or erosive reflux oesophagitis is well established. The aim of the current nationwide, multicentre ...

Two very different studies have recently been published, which indicate that use of intravenous PPIs as an adjunct to endoscopic hemostasis might effectively prevent recurrent ulcer bleeding. What do ...